Erratum: Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies.
null null
Published in: Frontiers in pharmacology (2024)
[This corrects the article DOI: 10.3389/fphar.2023.1182644.].